Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 43

1.
2.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Shen L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer's Disease Neuroimaging Initiative.

Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7. Review.

3.

Plasma biomarkers associated with the apolipoprotein E genotype and Alzheimer disease.

Soares HD, Potter WZ, Pickering E, Kuhn M, Immermann FW, Shera DM, Ferm M, Dean RA, Simon AJ, Swenson F, Siuciak JA, Kaplow J, Thambisetty M, Zagouras P, Koroshetz WJ, Wan HI, Trojanowski JQ, Shaw LM; Biomarkers Consortium Alzheimer's Disease Plasma Proteomics Project.

Arch Neurol. 2012 Oct;69(10):1310-7.

4.
5.

The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.

Weiner MW, Veitch DP, Aisen PS, Beckett LA, Cairns NJ, Green RC, Harvey D, Jack CR, Jagust W, Liu E, Morris JC, Petersen RC, Saykin AJ, Schmidt ME, Shaw L, Siuciak JA, Soares H, Toga AW, Trojanowski JQ; Alzheimer’s Disease Neuroimaging Initiative.

Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2. Review.

6.

1-[(1-methyl-1H-imidazol-2-yl)methyl]-4-phenylpiperidines as mGluR2 positive allosteric modulators for the treatment of psychosis.

Zhang L, Brodney MA, Candler J, Doran AC, Duplantier AJ, Efremov IV, Evrard E, Kraus K, Ganong AH, Haas JA, Hanks AN, Jenza K, Lazzaro JT, Maklad N, McCarthy SA, Qian W, Rogers BN, Rottas MD, Schmidt CJ, Siuciak JA, Tingley FD 3rd, Zhang AQ.

J Med Chem. 2011 Mar 24;54(6):1724-39. doi: 10.1021/jm101414h. Epub 2011 Mar 2.

PMID:
21366332
7.

3-Benzyl-1,3-oxazolidin-2-ones as mGluR2 positive allosteric modulators: Hit-to lead and lead optimization.

Duplantier AJ, Efremov I, Candler J, Doran AC, Ganong AH, Haas JA, Hanks AN, Kraus KG, Lazzaro JT Jr, Lu J, Maklad N, McCarthy SA, O'Sullivan TJ, Rogers BN, Siuciak JA, Spracklin DK, Zhang L.

Bioorg Med Chem Lett. 2009 May 1;19(9):2524-9. doi: 10.1016/j.bmcl.2009.03.032. Epub 2009 Mar 14.

PMID:
19328692
8.

The role of phosphodiesterases in schizophrenia : therapeutic implications.

Siuciak JA.

CNS Drugs. 2008;22(12):983-93. doi: 10.2165/0023210-200822120-00002. Review.

PMID:
18998737
9.

Preclinical characterization of selective phosphodiesterase 10A inhibitors: a new therapeutic approach to the treatment of schizophrenia.

Schmidt CJ, Chapin DS, Cianfrogna J, Corman ML, Hajos M, Harms JF, Hoffman WE, Lebel LA, McCarthy SA, Nelson FR, Proulx-LaFrance C, Majchrzak MJ, Ramirez AD, Schmidt K, Seymour PA, Siuciak JA, Tingley FD 3rd, Williams RD, Verhoest PR, Menniti FS.

J Pharmacol Exp Ther. 2008 May;325(2):681-90. doi: 10.1124/jpet.107.132910. Epub 2008 Feb 20.

10.

Behavioral characterization of mice deficient in the phosphodiesterase-10A (PDE10A) enzyme on a C57/Bl6N congenic background.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN, Harms JF, Schmidt CJ.

Neuropharmacology. 2008 Feb;54(2):417-27. Epub 2007 Dec 3.

PMID:
18061215
11.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Martin AN.

Psychopharmacology (Berl). 2008 Mar;197(1):115-26. Epub 2007 Dec 1.

PMID:
18060387
12.

Phosphodiesterase 10A inhibitors as a novel therapeutic approach for schizophrenia.

Siuciak JA, Strick CA.

Expert Opin Drug Discov. 2007 Jul;2(7):1001-9. doi: 10.1517/17460441.2.7.1001.

PMID:
23484819
13.

Behavioral and neurochemical characterization of mice deficient in the phosphodiesterase-1B (PDE1B) enzyme.

Siuciak JA, McCarthy SA, Chapin DS, Reed TM, Vorhees CV, Repaske DR.

Neuropharmacology. 2007 Jul;53(1):113-24. Epub 2007 Apr 29.

PMID:
17559891
14.

Disruption of the neurokinin-3 receptor (NK3) in mice leads to cognitive deficits.

Siuciak JA, McCarthy SA, Martin AN, Chapin DS, Stock J, Nadeau DM, Kantesaria S, Bryce-Pritt D, McLean S.

Psychopharmacology (Berl). 2007 Oct;194(2):185-95. Epub 2007 Jun 10.

PMID:
17558564
15.

Antipsychotic profile of rolipram: efficacy in rats and reduced sensitivity in mice deficient in the phosphodiesterase-4B (PDE4B) enzyme.

Siuciak JA, Chapin DS, McCarthy SA, Martin AN.

Psychopharmacology (Berl). 2007 Jun;192(3):415-24. Epub 2007 Mar 2.

PMID:
17333137
16.

CP-809,101, a selective 5-HT2C agonist, shows activity in animal models of antipsychotic activity.

Siuciak JA, Chapin DS, McCarthy SA, Guanowsky V, Brown J, Chiang P, Marala R, Patterson T, Seymour PA, Swick A, Iredale PA.

Neuropharmacology. 2007 Feb;52(2):279-90. Epub 2006 Sep 1.

PMID:
16949622
17.

Inhibition of the striatum-enriched phosphodiesterase PDE10A: a novel approach to the treatment of psychosis.

Siuciak JA, Chapin DS, Harms JF, Lebel LA, McCarthy SA, Chambers L, Shrikhande A, Wong S, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):386-96. Epub 2006 Jun 15.

PMID:
16780899
18.

Genetic deletion of the striatum-enriched phosphodiesterase PDE10A: evidence for altered striatal function.

Siuciak JA, McCarthy SA, Chapin DS, Fujiwara RA, James LC, Williams RD, Stock JL, McNeish JD, Strick CA, Menniti FS, Schmidt CJ.

Neuropharmacology. 2006 Aug;51(2):374-85. Epub 2006 Jun 12.

PMID:
16769090
19.

The activity of pramipexole in the mouse forced swim test is mediated by D2 rather than D3 receptors.

Siuciak JA, Fujiwara RA.

Psychopharmacology (Berl). 2004 Sep;175(2):163-9. Epub 2004 Feb 25.

PMID:
14985923
20.

Performance of heterozygous brain-derived neurotrophic factor knockout mice on behavioral analogues of anxiety, nociception, and depression.

MacQueen GM, Ramakrishnan K, Croll SD, Siuciak JA, Yu G, Young LT, Fahnestock M.

Behav Neurosci. 2001 Oct;115(5):1145-53.

PMID:
11584927
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk